# Ward Form (Mandatory : Fill in one form for each ward included in the PPS) Include only <u>in</u>patients "admitted before and present at 08:00 hours" on the day of the PPS!

Date of survey (dd/mm/year)	/	Perso	on completing form (Audito	r code) :			
Hospital name :			Ward	d Name :			
	Ac	lult wards			Paediatric wai	rds	
Ward Type:	☐ AMW (General or mixed Adult Medical Ward)	☐ <b>ASW</b> (General or m	ixed Adult Surgical Ward)		□ PMW (Paedi	iatric Medical Ward)	
Tick the most appropriate type	☐ <b>HO-AMW</b> (Haematology-Oncology)	☐ <b>DIG-ASW</b> (Digestive	e tract surgery)		☐ <b>HO-PMW</b> (Haematology-Oncology)		
of department/ward	☐ <b>T-AMW</b> (Transplant (BMT/solid))	☐ <b>ORT-ASW</b> (Orthopa	nedics-Trauma surg.)		□ T-PMW (Tra	nsplant (BMT/Solid))	
or department, war a	☐ <b>P-AMW</b> (Pneumology)	☐ <b>URO-ASW</b> (Urologi	cal surg.)		□ <b>PSW</b> (Paedia	atric Surgical Ward)	
	☐ CAR-AMW (Cardiology)	☐ <b>CV-ASW</b> (Cardio-va	scular surg.)		☐ <b>PICU</b> (Paedia	atric Intensive Care Unit)	
	□ <b>NEU-AMW</b> (Neurology)	☐ <b>NEU-ASW</b> (Neurosi	urgery)		□ <b>ID-PMW</b> (Inf	fectious Disease PMW)	
	☐ <b>REN-AMW</b> (Nephrology)	☐ ONCO-ASW (Oncol	ogy-cancer surg.)				
	☐ <b>ID-AMW</b> (Infectious Disease)	☐ <b>PLAS-ASW</b> (Plastic,	reconstructive surg.)		Neonatal war	ds:	
	☐ <b>DB-AMW</b> (Dermatology-burn wards)	☐ <b>ENT-ASW</b> (Ear-nose	e-throat surg.)		□ <b>NMW</b> (Neor	natal Medical Ward)	
	☐ <b>PSY-AMW</b> (Psychiatry)				□ <b>NICU</b> (Neona	atal Intensive Care Unit)	
	☐ <b>REH-AMW</b> (Rehabilitation)	☐ <b>AICU</b> (General or m	ixed Adult Intensive Care	Jnit)			
	☐ GER-AMW (Geriatrics)	☐ <b>MED-AICU</b> (Medica	I AICU)				
	☐ <b>LTC-AMW</b> (Long-Term care)	☐ <b>SUR-AICU</b> (Surgical	AICU)				
	☐ <b>OBG-AMW</b> (gynaecology-obstetrics)	☐ CAR-AICU (Cardiac	AICU)				
	☐ <b>IS-AMW</b> (Isolation ward, e.g. COVID patients)	☐ <b>AHDU</b> (High Depen	dency Unit)				
Mixed Ward	□ Yes □ No						
Activity: Tick as appropriate. In ca	ase of mixed wards, tick all encountered activities/spe	ecialities	☐ Medicine		Surgery	☐ Intensive Care	
Total number of admitted inpation	ents (=all patients whether they receive an antimicrob	oial or not !) on the					
ward present at 8.00 am on day of PPS. For mixed departments, fill the total number of patients		f patients					
corresponding to each of the encountered activities.							
	d present at 8:00 am on day of PPS split up by activity						
departments fill in the total numb	per of beds corresponding to each of the encountered	l activities.					



# GLOBAL-PPS PATIENT Form (Mandatory: Fill in one form per patient with an active/ongoing antimicrobial at 8am on the day of the PPS)

Patient Age 4

							1 44161147186		Current	70077466	reconded only (optional)	
Ward Name/code	Activity <sup>1</sup> (M, S, IC)	Patient	t Identifier <sup>2</sup>	Sur	vey Number <sup>3</sup>	Years ≥ 2 years	Months 1-23 month	Days <1 month	Weight* In kg	Gestatio- nal age*	Birth weight* (kg)	Sex M, F, U
Treatment based on bio	marker data	or WBC	0 Yes - 0	) No		Culture(s) sent t	o the lab to do	cument infec	tion* (Tick if	yes)		
	Тур				nt value close to	Blood	Cereb	rospinal flui	d	BAL (pro	tected resp. spe	ecimen)
If yes, which: CRP, PCT, other	san	logical fluid nple		start antimic Value	robial Unit <sup>6</sup>	☐ Urine	☐ Wour	nd (surgery/k	oiopsy)	☐ Sputum/	bronchial aspira	ate
or WBC <sup>5</sup>	(Blo	ood/urine/ er)				☐ Stool	Other	r type of spe	cimen			
Antimicrobial Name <sup>7</sup>			1.		2.		3.		4.		5.	
Start date of the antim	nicrobial* ( <i>dd/</i>	/mm/yyyy)										
Single Unit Dose 8	Unit (g, mg, l	U, MU) <sup>9</sup>										
Doses/ day 10	Route (P, O,	R, I, IM) <sup>11</sup>										
Diagnosis 12 (see apper	ndix II)											
Type of indication <sup>13</sup> (s	ee appendix II	l)										
Reason in Notes (Yes o	or No) <sup>14</sup>											
<b>Guideline Compliance</b>	(Y, N, NA, NI)	15										
Is a stop/review date of	documented?	(Yes/No)										
N missed doses*16	Reason* (S	,P,D,O,M,U)	17									
Treatment (E: Empirica	al; T: Targeted	)18										
The following resista			in only if the	treatment o	choice is based	on microbiolog	y data (Treati	ment=T) ava	ailable on th	ne day of the	PPS	
Maximum 3 microorga Maximum 1 Resistance	anisms (MO) t	o report	МО	R type		R type**	МО	R type**	МО	R type**		R type**
Insert codes (see Appe	endix IV, page	9) MO	1									
		MC	) 2									
		140										

<u>Resistance type</u>\*\*- choose between: MRSA<sup>19</sup>; MRCoNS<sup>20</sup>; PNSP<sup>21</sup>; MLS<sup>22</sup>; VRE<sup>23</sup>; ESBL (ESBL-producing Enterobacterales<sup>24</sup>); 3GCREB (3<sup>rd</sup> generation cephalosporin resistant Enterobacterales); CRE (Carbapenem-resistant Enterobacterales<sup>25</sup>); ESBL-NF (ESBL-producing non fermenter Gram-negative bacilli<sup>26</sup>); CR-NF (Carbapenem-resistant non fermenter Gram-negative bacilli<sup>27</sup>); other MDRO<sup>28</sup>; Azoles<sup>29</sup>. Encode Microorganism also if resistance type is unknown.

Note: \* Current weight, Gestational age (in number of weeks), Birth weight, Start date of the antimicrobial and Cultures sent to the lab, missed doses are optional variables.



**Neonate only** (optional)

- Activity: M=medicine (including Psychiatric cases, etc.), S=surgery (including orthopaedics, obstetrics and gynaecology, etc.), IC=intensive care
- <sup>2</sup> Patient Identifier: A unique patient identifier that allows linkage to patient records at local level for more detailed audit. This unique identifier will not be included in the online database.
- <sup>3</sup> <u>Survey Number</u>: A unique non-identifiable number given by WebPPS for each patient entered in the database. Leave blank but note down the number after the patient data has been recorded in the online database. The number is displayed once (and only) after the patient data has been recorded in the online database.
- <sup>4</sup> Patient Age: If the patient is 2 years old or older, specify only the number of years, if between 1 and 23 months specify only the number of months, if less than 1 month specify the number of days.
- 5 If treatment based on biomarker, specify which one: **CRP** (C-reactive protein), **PCT** (Procalcitonin), **Other** lab-based biomarker other than CRP, PCT; or **WBC** (white blood cell count).
- <sup>6</sup> The unit for the biomarker CRP or PCT value expressed in mg/L, μg/L, ng/L, ng/dL, ng/dL, ng/mL, nmol/L. In thousand per microliter (μL) for WBC count (normal number of WBCs in the blood is 4,500 to 11,000 WBCs per microliter). For a conversion calculator see: <a href="http://unitslab.com/node/67">http://unitslab.com/node/103</a> (procalcitonin).
- <sup>7</sup> Antimicrobial Name: Insert generic name.
- <sup>8</sup> Single Unit Dose: Numeric value for dose per administration (in grams, milligrams, IU or MU).
- <sup>9</sup> <u>Unit</u>: The unit for the dose (g, mg, IU or MU)
- Doses/day If necessary provide fractions of doses: (e.g., every 16h = 1.5 doses per day, every 36h = 0.67 doses per day, every 48h = 0.5 doses per day)
- 11 Route: Routes of administration are: Intravenous and intrathecal and intraperitoneal=P, Intramuscular=IM, Oral=O, Rectal=R, Inhalation=I. See also protocol page 18
- <sup>12</sup> See <u>diagnoses</u> groups list (Appendix II)
- <sup>13</sup> See <u>Indication</u> codes (Appendix III)
- Reason in Notes: A diagnosis / indication for treatment is recorded in the patient's documentation (treatment chart, notes, etc.) at the start of antibiotic course (Yes or No)
- <sup>15</sup> <u>Guideline Compliance</u>: Refers to antibiotic choice (not route, dose, duration etc) in compliance with **local** guidelines (Y: Yes; N: No; NA: Not Assessable because of absence of local guidelines for the specific indication; NI: No Information because diagnosis/indication is unknown)
- <sup>16</sup> N missed doses: Number of missed doses from start date of current antibiotic treatment until the date of the survey. If no doses missed, report as 0. If unknown, leave field empty.
- <sup>17</sup> Reason: Reason for missed doses: due to **stock** out (S), patient could not **purchase** (P), patient **declined**/refused (D), **other** reason (O), **multiple** reasons (M), **unknown** (U).
- Treatment: Report "E" 1) when the antibiotic is being used as per a local guideline, treatment by which experience has proved to be beneficial; 2) when a culture or microbiological examination is not done; 3) when a microbiological examination is done, BUT not yet available on the day of the PPS; or the result was not assessable. Report "T" if based upon microbiological result; Report also "T" if the micro-organism yielded susceptible results.
- <sup>19</sup> Methicillin-resistant *Staphylococcus aureus* (MRSA)
- <sup>20</sup> Methicillin-resistant coagulase negative staphylococci (MRCoNS)
- <sup>21</sup> Penicillin-non susceptible *Streptococcus pneumoniae* (PNSP)
- <sup>22</sup> Macrolide-lincosamide-streptogramin resistance in Streptococcus isolates (MLS)
- <sup>23</sup> Vancomycin-resistant enterococci (VRE)
- <sup>24</sup> Bacteria, producing extended-spectrum beta-lactamases (ESBL)
- <sup>25</sup> Carbapenem-resistant *Enterobacterales* (CRE) enteric bacteria resistant to imipenem, meropenem or other carbapenems
- <sup>26</sup> ESBL Non fermenters (ESBL-NF): *Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia spp., Stenotrophomonas maltophilia* multidrug resistant
- <sup>27</sup> Carbapenem-resistant Nonfermenters (CR-NF) nonfermenters resistant to imipenem, meropenem or other carbapenems
- <sup>28</sup> Multi-drug resistant (MDR) pathogens, others than the listed above
- <sup>29</sup> Azoles: if the medicinal product chosen is intended to treat infections caused by azole-resistant fungi and yeasts (e.g. *Candida spp., Aspergillus spp.*)

## HOSPITAL PROFILE - "Optional data" to be collected at hospital level

Provide, if available, for each indicator the year of reference and the number "at hospital level".

<u> </u>		
	Year (yyyy)	Number
Hospital size: number (N) beds		
Number of admissions (or discharges)/year		
Number of patient days or occupied bed-days/year		
Number of consumption of alcohol-based hand rub in litres/year		
Number of "patients" with blood culture test/year		
Number of stool tests for Clostridioides difficile Infections/year		
Number of FTE* antimicrobial stewardship physicians		
Number of FTE antimicrobial stewardship pharmacists		
Number of FTE Infection prevention control (IPC) doctors		
Number of FTE Infection prevention control (IPC) nurses		
V		1.1.1

Indicate for each indicator at hospital level if available 'yes' or 'no'

	Yes	If yes: Year of introduction	No
Presence of formally defined AMS* program			
Presence of active AMS group (committee and operational team)			
Presence of formally defined IPC* program			
Presence of active IPC group (committee and operational team)			
Presence of regular IPC (annual, quarterly) feedback to health care workers			
Clinical Infectious Disease (ID) consultation available			
Specialized AMS or ID training available for physicians/pharmacists			
Presence of microbiology lab support on site			
Availability of microbiology lab on weekends/holidays			
Availability of periodic cumulative antimicrobial susceptibility report**			
If yes, is susceptibility report distributed to prescribers?			
Availability of standardized criteria for appropriate IV-PO switch			
Software available for Infection Control and/or AMS			
Presence of bundles or checklists to decrease CAUTI, VAP, CR-BSI, CDIF, SSI°			

<sup>\*</sup>AMS=Antimicrobial Stewardship; IPC=Infection Prevention and Control; \*\* local epidemiological report

Tick for each indicator if available at hospital level.

Availability of written policy to document the antimicrobial prescription in the medical record	Yes, all wards	Yes, selected wards	Yes, in ICU	No
Availability of <b>formal restriction procedure</b> (defined formulary, restrictive list) for certain antimicrobials	Yes, all wards	Yes, selected wards	Yes, in ICU	No
Presence formal review of antimicrobial after 48 hours (post-prescription review)	Yes, all wards	Yes, selected wards	Yes, in ICU	No
Presence of <b>antimicrobial ward rounds</b> (Review of antimicrobial orders for assigned patients)	Yes, all wards	Yes, selected wards	Yes, in ICU	No
Who can prescribe antibiotics in your hospital?	Physician	Pharmacist	Nurse	Other

<sup>\*</sup>FTE=Full-Time Equivalent units or equivalent employees working full-time on antimicrobial stewardship activities or IPC. E.g. if 3 employees work 20 hours, 30 hours and 10 hours/week=total 60 hours/week and assuming that a full-time employee works 40hours/week, the FTE calculation equals 60hours/40hours; or 1.5 FTE

<sup>°</sup> CAUTI=Catheter Associated Urinary Tract Infection; VAP=Ventilator Associated Pneumonia; CR-BSI=Catheter-related Blood Stream Infection; CDIF= Clostridioides Difficile Infection; SSI=Surgical Site Infections.

#### **Appendix I: Combination anti-infective agents**

#### Combinations of an antibiotic and a beta-lactamase inhibitor:

Do not report the dose of the beta-lactamase inhibitor

Ampicillin and beta-lactamase inhibitor: report only ampicillin dose (J01CR01)
Amoxicillin and beta-lactamase inhibitor: report only amoxicillin dose (J01CR02)
Ticarcillin and beta-lactamase inhibitor: report only ticarcillin dose (J01CR03)
Piperacillin and beta-lactamase inhibitor: report only piperacillin dose (J01CR05)
Imipenem and beta-lactamase inhibitor: report only imipenem dose (J01DH51)
Panipenem and betamipron: report only panipenem (J01DH55)

#### Example:

Amoxicillin and beta-lactamase inhibitor 1.2g IV  $\rightarrow$  1g (amoxicillin) + 200mg (clavulanic acid), **report** only 1 g as unit dose

Piperacillin and beta-lactamase inhibitor 4.5g IV → 4g (piperacillin) + 500mg (tazobactam), **report** only 4 g as unit dose

#### Other combinations of multiple antimicrobial substances:

J01EE01 Sulfamethoxazole and Trimethoprim: report the total amount of sulfamethoxazole and trimethoprim

Example:

Co-trimoxazole 960mg: (sulfamethoxazole. 800mg + trimethoprim 160mg), report 960mg

Further information on agents included for the Global-PPS is available in the antimicrobial list. Only antimicrobial substance name needs to be written down, NOT the ATC codes! (excel file - available on website under documents: Global-PPS\_antimicrobial\_list.xlsx) <a href="http://www.global-pps.com/">http://www.global-pps.com/</a>

Appendix II - Diagnostic therapeutic / treatment codes (what the clinician aims at treating)

Site	Codes	Examples
CNS	CNS	Infections of the Central Nervous System
EYE	EYE	Therapy for Eye infections e.g., Endophthalmitis
ENT	ENT	Therapy for Ear, Nose, Throat infections including mouth, sinuses, larynx
i	AOM	Acute otitis media
RESP	LUNG	Lung abscess including aspergilloma
İ	URTI	Upper Respiratory Tract viral Infections including influenza but not ENT
İ	Bron	Acute <b>Bron</b> chitis or exacerbations of chronic bronchitis
İ	Pneu	Pneumonia or LRTI (lower respiratory tract infections)
İ	COVID-19	Coronavirus disease caused by SARS-CoV-2 infection
İ	ТВ	Pulmonary TB (Tuberculosis)
İ	CF	Cystic fibrosis
CVS	CVS	CardioVascular System infections: endocarditis, endovascular device e.g pacemaker, vascular graft
GI	GI	Gastro-Intestinal infections (salmonellosis, Campylobacter, parasitic, etc.)
ı	IA	Intra-Abdominal sepsis including hepatobiliary, intra-abdominal abscess etc.
i	CDIF	Clostridioides difficile infection
SSTBJ	SST	Skin and Soft Tissue: Cellulitis, wound including surgical site infection, deep soft tissue not involving
İ		bone e.g., infected pressure or diabetic ulcer, abscess
	BJ	Bone/Joint Infections: Septic arthritis (including prosthetic joint), osteomyelitis
UTI	Cys	Lower Urinary Tract Infection (UTI): cystitis
i	Pye	Upper UTI including catheter related urinary tract infection, pyelonephritis
	ASB	Asymptomatic bacteriuria
GUOB	OBGY	Obstetric/Gynaecological infections, Sexually Transmitted Diseases (STD) in women
İ	GUM	Genito-Urinary Males + Prostatitis, epididymo-orchitis, STD in men
	Syph	Syphilis
No	BAC	Bacteraemia or fungaemia with no clear anatomic site and no shock
defined	SEPSIS	Sepsis of any origin (eg urosepsis, pulmonary sepsis etc), sepsis syndrome or septic shock with no
site		clear anatomic site. Include fungaemia (candidemia) with septic symptoms
(NDS)	Malaria	
İ	HIV	Human immunodeficiency virus
ı	PUO	Pyrexia of Unknown Origin - Fever syndrome with no identified source or site of infection
ı	PUO-HO	Fever syndrome in the non-neutropenic Haemato-Onco patient with no identified source of pathogen
ı	FN	Fever in the Neutropenic patient
ı	LYMPH	Lymphatics as the primary source of infection eg suppurative lymphadenitis
ı	Sys-DI	Disseminated infection (viral infections such as measles, CMV)
ı	Other	Antimicrobial prescribed with documentation but no defined diagnosis group
ı	UNK	Completely <b>Unk</b> nown Indication
	PROK	Antimicrobial (e.g. erythromycin) prescribed for <b>Prok</b> inetic use

Appendix II, next - Codes for surgical and medical prophylaxis

Site	Codes	Examples
CNS	Proph CNS	Prophylaxis for CNS (neurosurgery, meningococcal)
EYE	Proph EYE	Prophylaxis for Eye operations
ENT	Proph ENT	Prophylaxis for Ear, Nose, Throat (Surgical or Medical prophylaxis=SP/MP)
RESP	Proph RESP	Pulmonary surgery, prophylaxis for <b>Resp</b> iratory pathogens e.g. for aspergillosis
CVS	Proph CVS	Cardiac or Vascular Surgery, endocarditis prophylaxis
GI	Proph GI	Gastro-Intestinal tract surgery, liver/biliary tree, GI prophylaxis in neutropenic patients or
		hepatic failure
SSTBJ	Proph BJ	Prophylaxis for SST, for plastic or orthopaedic surgery (Bone or Joint)
UTI	Proph UTI	Prophylaxis for urological surgery (SP) or recurrent Urinary Tract Infection (MP)
GUOB	Proph OBGY	Prophylaxis for <b>OB</b> stetric or <b>GY</b> naecological surgery (SP: section caesarean, no episiotomy;
		MP: carriage of group B streptococcus)
No	MP-GEN	Drug is used as <b>M</b> edical <b>P</b> rophylaxis in <b>gen</b> eral, without targeting a specific site, e.g.
defined		antifungal prophylaxis during immunosuppression
site		
(NDS)		

**Appendix II, next - Codes for Neonates** 

Site	Codes	Examples
Neonatal	MP-MAT	Medical Prophylaxis for Maternal risk factors e.g. maternal prolonged rupture membranes
	NEO-MP	Drug is used as <b>M</b> edical <b>P</b> rophylaxis for <b>Newborn</b> risk factors e.g. VLBW (Very Low Birth Weight) and IUGR (Intrauterine Growth Restriction)
	CLD	Chronic lung disease: long-term respiratory problems in premature babies (bronchopulmonary dysplasia)

## **APPENDIX III - Type of Indication**

<b>CAI</b> Community acquired infection		Symptoms started ≤ 48 hou admission).	Symptoms started ≤ 48 hours from admission to hospital (or present on admission).						
<u>HAI</u>		HAI1 Post-operative surgical site infection (within: 30 days of surgery OR; 90 days after implant surgery)							
Healthcare Associated		HAI2 Intervention related infections of mixed origin (mixed infection such as mix of CVC-BSI, PVC-BSI, VAP, CAUTI; or related to tubes/drains)							
Infection: Symptoms	Device related	HAI2-CVC-BSI (Central Ve	enous <b>Catheter</b> -related E	Blood Stream Infection)					
start 48 hours	HAI	HAI2-PVC-BSI (Peripheral	Vascular Catheter-relat	ed Blood Stream Infection)					
after		HAI2-VAP (Ventilator Asso	ociated <b>Pneumonia</b> )						
admission to hospital		HAI2- CAUTI (Catheter As	sociated <b>Urinary</b> Tract I	nfection)					
'		HAI3 C. difficile associated days after discharge from p							
		HAI4 Other hospital acquire BSI)	ed infection of mixed or	undefined origin (HAP, UTI,					
		HAI4-BSI Blood Stream Infection, not intervention related							
		<u>HAI4-HAP</u> Non-intervention related Hospital Acquired <b>Pneumonia</b> (not VAP)							
		HAI4-UTI Urinary Tract Infection, not intervention related							
		HAI5 Patient referred from another to the participating hospital with an existing HAI determined and documented on Day 1 of admission or patient readmitted <48h after stay in another hospital, with infection present on current admission or within 48 hours (patient with infection from another hospital).							
		HAI6 Infection present on admission from long-term care facility (LTCF) or Nursing Home*							
SP Surgical prophylaxis**		SP1 Single dose	SP2 one day	<b>SP3</b> >1 day					
•	ler to end	dministration of prophylactic a code the duration of prophylax r >1 day.		•					
See more expla	anation a	nd <b>table</b> in <b>protocol page 8</b> !							
MP Medical prophylaxis									
OTH Other	F	For example erythromycin as a motility agent (motilin agonist).							
<u>UNK</u>	C	Completely unknown indication							

#### Select 1 possibility for each reported antimicrobial

<sup>\*</sup>Long-term care facilities represent a heterogeneous group of healthcare facilities, with care ranging from social to medical care. These are places of collective living where care and accommodation is provided as a package by a public-agency, non-profit or private company (e.g. nursing homes, residential homes). \*\*Surgical prophylaxis includes those antibiotics prescribed before and after a surgical intervention (surgery in the operation room). The code SP1, SP2, SP3 goes with a diagnostic code preceded by 'proph' (e.g. 'proph GI')

# APPENDIX IV – list of micro-organisms by resistance type

ti i Eitenx iv liot of filloro orga		_		
Microorganisms (MO)	Code	Resistance type - 1	Resistance type - 2	Resistance type - 3
Staphylococcus aureus	STAAUR	MRSA		
Staphylococcus epidermidis	STAEPI	MRCoNS		
Staphylococcus haemolyticus	STAHAE	MRCoNS		
Other coagulase-negative staphylococci (CNS)	STAOTH	MRCoNS		
Streptococcus pneumoniae	STRPNE	PNSP	MLS	
Streptococcus spp., other or not specified	STROTH	MLS		
Enterococcus faecalis	ENCFAE	VRE		
Enterococcus faecium	ENCFAI	VRE		
Enterococcus spp. , other or not specified	ENCOTH	VRE		
Neisseria meningitidis	NEIMEN	Other MDRO		
Neisseria gonorrhoeae	NEIGON	Other MDRO		
Listeria monocytogenes	LISMON	Other MDRO		
Citrobacter freundii	CITFRE	ESBL	3GCREB	CRE
Citrobacter spp. , other or not specified	СІТОТН	ESBL	3GCREB	CRE
Enterobacter cloacae	ENBCLO	ESBL	3GCREB	CRE
Enterobacter spp., other or not specified	ENBOTH	ESBL	3GCREB	CRE
Escherichia coli	ESCCOL	ESBL	3GCREB	CRE
Klebsiella aerogenes	KLEPAE	ESBL	3GCREB	CRE
Klebsiella pneumoniae	KLEPNE	ESBL	3GCREB	CRE
Klebsiella oxytoca	KLEOXY	ESBL	3GCREB	CRE
Klebsiella spp., other or not specified	KLEOTH	ESBL	3GCREB	CRE
Proteus mirabilis	PRTMIR	ESBL	3GCREB	CRE
Proteus vulgaris	PRTVUL	ESBL	3GCREB	CRE
Proteus spp., other or not specified	PRTOTH	ESBL		CRE
Serratia marcescens	SERMAR	ESBL	3GCREB	CRE
	SEROTH	ESBL	3GCREB	CRE
Serratia spp., other or not specified			3GCREB	
Morganella spp.	MOGSPP	ESBL	3GCREB	CRE
Providencia spp.	PRVSPP	ESBL	3GCREB	CRE
Salmonella enteritidis	SALENT	ESBL	3GCREB	
Salmonella typhi or paratyphi	SALTYP	ESBL	3GCREB	
Salmonella typhimurium	SALTYM	ESBL	3GCREB	
Salmonella spp., other or not specified	SALOTH	ESBL	3GCREB	
Shigella spp.	SHISPP	ESBL	3GCREB	
Yersinia spp.	YERSPP	ESBL	3GCREB	
Other Enterobacterales	ETBOTH	ESBL	3GCREB	CRE
Acinetobacter baumannii	ACIBAU	ESBL-NF	CR-NF	
Acinetobacter spp., other or not specified	ACIOTH	ESBL-NF	CR-NF	
Pseudomonas aeruginosa	PSEAER	ESBL-NF	CR-NF	
Stenotrophomonas maltophilia	STEMAL	CR-NF		
Burkholderia cepacia	BURCEP	CR-NF		
Burkholderia pseudomallei	BURPSE	CR-NF		
Burkholderia mallei	BURMAL	CR-NF		
Pseudomonadaceae family , other or not specified	PSEOTH	ESBL-NF	CR-NF	
Campylobacter spp.	CAMSPP	Other MDRO		
Helicobacter pylori	HELPYL	Other MDRO		
Clostridioides difficile	CLODIF	Other MDRO		
Clostridium spp., other or not specified	CLOOTH	Other MDRO		
Other bacteria Mycobacterium, atypical	MYCATY	Other MDRO		
Mycobacterium tuberculosis complex	MYCTUB	Other MDRO		
Other bacteria	OTHER	Other MDRO		
Candida spp.	CANSPP	Azoles		
Aspergillus spp.	ASPSPP	Azoles		
Other fungi	, 51 51 1	720103		